AVI BIOPHARMA - Schweinegrippe-Profiteur
Seite 4 von 6 Neuester Beitrag: 29.11.12 14:30 | ||||
| Eröffnet am: | 27.04.09 19:22 | von: Fortunatus | Anzahl Beiträge: | 133 |
| Neuester Beitrag: | 29.11.12 14:30 | von: MeinMotto | Leser gesamt: | 38.825 |
| Forum: | Hot-Stocks | Leser heute: | 11 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | | 5 | 6 > | ||||
12:02 07.07.09
Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" raten bei der Aktie von AVI BioPharma (Profil) mit einer kleinen spekulativen Position aufzuspringen.
Vor wenigen Tagen habe das Unternehmen einen Auftrag in Höhe von 5,1 Mio. USD von der US-Regierung erhalten. Bereits Anfang Mai sei mit der US-Defense-Threat-Reduction-Agency eine Vereinbarung zur Entwicklung mindestens eines Produktkandidaten gegen die Schweinegrippe getroffen worden. Nun sei dieser Deal endgültig fixiert worden.
Aktuell entwickle AVI BioPharma in Phase I die beiden Wirkstoffe AVI-6002 und AVI-6003 zur Behandlung von Ebola und des Marburg-Virus. Zusätzlich treibe das Unternehmen - teilweise auch in Zusammenarbeit mit Partnerunternehmen - Forschungsreihen im Bereich von Herz-/Kreislauferkrankungen und bei DMD, einer bislang tödlich verlaufenden Muskelerkrankung, voran. Diese Produktpipeline sei zwar spannend, da sich aber alles noch in einer frühen Forschungsphase befinde werde es noch Jahre dauern, bis das Unternehmen damit Geld verdiene. Deshalb seien unerwartete Aufträge wie aktuell seitens der US-Regierung ein Segen für AVI BioPharma. Eines sei sicher: Bringe das Unternehmen nur einen seiner Produktkandidaten zur Marktreife, würde dies einen Durchbruch für die nur USD 120 Mio. schwere Gesellschaft bedeuten.
Branchenexperten seien vom mittelfristigen Potenzial des Unternehmens komplett überzeugt. Neben dem Regierungsauftrag würden der Aktie derzeit auch durch die Aufnahme in den Russell 3000 Index Beine gemacht.
Die Experten von "Global Biotech Investing" empfehlen bei der Aktie von AVI BioPharma mit einer kleinen spekulativen Position auf die laufende Rally aufzuspringen. (Ausgabe 13 vom 06.07.2009) (07.07.2009/ac/a/a)
Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.
Quelle: Aktiencheck
Im Kampf gegen die Schweinegrippe planen die USA im Herbst eine Massenimpfung. Die Gesundheitsbehörden wollen bis Mitte Oktober 100 Millionen Einheiten eines Impfstoffs zur Verfügung stellen.
Die Impfaktion soll sich auf Schulkinder, Schwangere sowie chronisch Kranke und Krankenhaus-Beschäftigte konzentrieren, die als besonders gefährdet durch das H1N1-Virus gelten.
Bisherigen Schätzungen zufolge sollen bereits eine Million Amerikaner an Schweinegrippe erkrankt sein – 170 starben, dies berichtete die „Washington Post“.
Bei der Weltgesundheitsorganisation (WHO) sind bislang rund 35 000 Erkrankungen in den USA registriert, Mediziner gehen aber weltweit von einer sehr großen Dunkelziffer aus. Experten warnten auf einem Gesundheitsgipfel vor der Einschätzung, dass die Pandemie bereits vorüber sei.
Vor einem Beginn der Massenimpfungen müsse aber zunächst garantiert werden, dass der Impfstoff sicher und effektiv sei – entsprechende Tests seien für August geplant, berichtete die „New York Times“. Da es aber vermutlich nicht genügend Impfstoff für die gesamte Bevölkerung gebe, müsse man sich zunächst auf Risikogruppen beschränken.
Die Bundesregierung will in der kommenden Woche festlegen, welche Bevölkerungsgruppen in Deutschland gegen die Schweinegrippegeimpft werden sollten.
„Wir müssen entscheiden, wer zu den Risikogruppen gehört“, sagte Bundesgesundheitsministerin Ulla Schmidt (SPD) dem Hörfunksender Hit-Radio Antenne Niedersachsen.
Dazu dürften die Beschäftigten im Gesundheitswesen, aber auch junge Menschen mit Grunderkrankungen gehören.
Für diese Gruppen solle eine Impfempfehlung ausgesprochen werden, so die Gesundheitsministerin.
Die Bestelloptionen für Grippemittel reichten aus, um jeden Deutschen zweimal zu impfen. Unklar sei noch, ob bei älteren Menschen eine Impfung sinnvoll sei, sagte Schmidt. In dieser Altersgruppe gebe es kaum Erkrankungen. Möglicherweise reiche hier der normale saisonale Grippeimpfstoff aus.
PORTLAND, OR -- (MARKET WIRE) -- 07/14/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Fred Schnell of AVI presented at the American Society of Virology Annual Meeting which took place July 11-15 in Vancouver, B.C. The title of the presentation was "Pan-Arenavirus Antisense Therapeutic Based On PMOplus(TM) Chemistry." In addition to Dr. Schnell, Drs. Bestwick, Iversen and Mourich, all of AVI, coauthored the presentation.
Schnell presented results of preclinical findings using an antiviral oligomer compound that incorporates AVI's proprietary backbone chemistry (PMOplus(TM)). The work shows that a single oligomer blocks a terminal sequence common to the eight distinct RNAs expressed by viruses from the family of hemorrhagic fever arenaviruses. Because this sequence is highly conserved among arenaviruses, a single agent might serve as a pan-arenavirus drug. Arenaviruses include Lassa fever, lymphocytic choriomeningitis, Junin and Machupo viruses, all members of the Class A bioterrorism pathogen list.
"We believe that the PMOplus(TM) chemistry is particularly useful for targeting potential variable or mutation prone sequences within the viral RNA," said Ryszard Kole, AVI Senior V.P. Discovery Research. "This chemistry, combined with the fact that a single agent blocks RNAs involved in several steps of the viral life cycle of a whole family of viruses, makes this approach to viral drug discovery look very promising."
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA-based therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com
Action Duchenne Provides $1.2m to Support Continuing Development of Drugs to Treat Duchenne Muscular Dystrophy
CORVALLIS, OR and LONDON -- (MARKET WIRE) -- 07/28/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, and Action Duchenne, a leading UK charity dedicated to increasing awareness, engendering action and raising funds to find a cure for Duchenne Muscular Dystrophy (DMD), today announced a collaboration to support the acceleration of research and development for AVI's exon skipping candidate drugs for the treatment of DMD.
"AVI has a new class of candidate drugs which are an important contribution to Action Duchenne's search for a treatment for DMD. We have teamed up with AVI to help accelerate these clinical programs as part of our commitment to cure this devastating disease," said Nick Catlin, CEO of Action Duchenne. "Our primary goal is to help provide treatment options for the many children and adults afflicted with DMD. We believe we can provide significant value to AVI's ground breaking efforts."
"AVI and Action Duchenne share a common goal to advance new therapeutics and find treatment options for DMD patients," said Leslie Hudson, Ph.D., President and Chief Executive Officer of AVI BioPharma. "We believe this collaboration has high potential and we are also very pleased to receive the financial support from Action Duchenne which will help accelerate our research and development efforts for new exon skipping therapeutics."
The agreement has a one-year term, with an option to extend for additional years, and will provide approximately $1.2 million in support to AVI over the initial term for advancement of research, regulatory efforts and clinical trial recruitment.
AVI is currently conducting a dose-finding clinical trial evaluating the systemic delivery of AVI-4658. This is an open label, 12 week safety trial, which includes measures of drug efficacy and pharmacokinetics, being conducted in London, UK, at the UCL Institute of Child Health/Great Ormond Street Hospital NHS Trust facilities and at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK, which is the center for the European Treat Neuromuscular Diseases (Treat-NMD) initiative. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.
AVI-4658 is designed to skip exon 51 of the dystrophin gene, allowing for restoration of the reading frame in the mRNA sequence. By skipping this exon, a truncated, yet potentially functional form of the dystrophin protein is produced, which could ameliorate the disease process and possibly prolong and improve the quality of life of these patients. Results from a Phase 1 proof-of-concept trial showed that injection of the drug into the muscles of a series of DMD boys successfully induced dystrophin production in a dose-responsive manner. Further, the drug was well tolerated, with no significant drug-related adverse events detected. The clinical trial was conducted in collaboration with the MDEX Consortium in London, UK. AVI is also developing AVI-5038, a new candidate drug based on second-generation PPMO chemistry and designed to skip exon 50. The preclinical work for AVI-5038 is funded in part by Charlie's Fund. The Company is currently working to advance this new drug candidate into clinical trials under an investigational new drug application (IND) in the United States and an investigational medicinal product dossier (IMPD) in Europe.
About Duchenne Muscular Dystrophy (DMD)
DMD is the most common fatal genetic disorder to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with Duchenne Muscular Dystrophy with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children before age six. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time in decades, there are promising therapies in or moving into development.
About Action Duchenne
Action Duchenne (formally Parent Project UK) was set up by Duchenne families in 2001 to promote new research for a cure for Duchenne. The charity has a strong record in funding research and has to date funded 9 major projects costing over £1m and has been a leading partner in the £1.6m DoH MDEX project. These projects have enabled much needed early work to be completed on exon skipping and other therapeutic approaches.
Action Duchenne holds an international conference every year to bring together researchers and families to exchange new research developments and provide a vital meeting venue for scientists.
In 2005 Action Duchenne launched the Duchenne Registry, the first National Duchenne database that holds gene information of people living with Duchenne and can be used to speed up the recruitment of patients for clinical trials. In 2006 Action Duchenne launched a comprehensive learning and behaviour toolkit for use by parents and education professionals. For more information please visit: www.actionduchenne.org
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com
Action Duchenne Contacts:
Nick Catlin
CEO
Action Duchenne
+44 (0) 20 8556 9955
Email: nick@actionduchenne.orgAndreina West
PR Artistry
+44 (0) 1491 639500
email: Andreina@pra-ltd.co.uk
AVI BioPharma Announces Second Quarter 2009 Financial Results Conference Call
For Immediate Release
CORVALLIS, OR — August 3, 2009 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will hold a conference call to report second quarter 2009 financial results on Monday, August 10, 2009, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time).
Individuals interested in listening to the live conference call may do so by dialing 800-967-7135 toll free within the United States and Canada, or 719-457-2603 for international callers.
A replay of the call will be available by dialing 888-203-1112 toll free within the U.S. and Canada or 719-457-0820 for international callers. The passcode for the replay is 4026242. In addition, a recording of the call will be available within approximately 24 hours at www.avibio.com.
Optionen
| Boardmail an "Vermeer" |
Wertpapier: Sarepta Therapeutics In |
http://quotes.nasdaq.com/asp/...ote.asp?symbol=AVII&selected=AVII